Evaluation of treatment efficacy in “real life” within National Treatment centres, and comparison of SVR among patients treated with commercially available and locally produced pegylated interferon

Following the demonstration of the efficacy of pegylated interferon and ribavirin in patients with genotype 4 chronic hepatitis C, the Egyptian government decided to provide free or highly subsidized treatments through a National Treatment Program. This program started in 2006 and counted 23 treatment centers in 2012. More than 200 000 patients have been treated since the beginning of the program, with either Pegasys® (Roche) or PegIntron® (MSD) in roughly equal numbers. In parallel, Health Insurance Organization (HIO) provided free treatment for chronic hepatitis C to about 20 000 civil servants registered in their organization, using the locally produced pegylated interferon alpha-2a called Reiferon® (Minapharm). Our aim in this study was to evaluate the efficacy of chronic hepatitis C treatment in “real life” and to compare the efficacy of the locally produced pegylated interferon with that of known products like Pegasys® and Pegintron®. Analyses are on-going and should be available soon.


Back to on-going & planned research work


Introduction of Sofosbuvir in Egypt

In July 2014, Gilead and the Egyptian government signed an agreement for a treatment expansion of Sovaldi® (Sofosbuvir). Read more

Scientific Advisory Board Meeting

The Scientific Advisory Board Meeting was held in Paris February 15-16, 2013.

Read more

fp7_01fp7_02 This project is funded
by the European Union